Retinal Drugs Market Size to Grow by $ 6.28 bn through 2021-2025
Technavio research projects the retinal drugs market to grow by $ 6.28 bn, accelerating at a CAGR of over 6% till 2025. The growth trajectory of the market is traced through a detailed analysis of the prevalent market forces, trends, and drivers along with competitive benchmarking
Retinal Drugs Market: Receive FREE Sample Report
Retinal Drugs Market: Key Market Driver
One of the primary factors that will trigger the growth of the retinal drugs market size is Rise in prevalence of retinal diseases. This research report provides a comprehensive analysis of all the factors that are likely to propel market growth, taking into account the market trends as well as challenges that are likely to impede growth. The objective of this research report is to equip clients with actionable insights that will help them leverage opportunities and formulate growth strategies for their business.
Retinal Drugs Market: Vendor Analysis
The market is fragmented due to the presence of several players. The growth of the players depends on several factors such as market conditions, government support, and industry development. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions. AbbVie Inc., Aerie Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments.
Technavio also offers custom research reports with detailed insights assessing the market from a global as well as regional perspective. This customized report will help clients keep up with new product launches in direct & indirect or related markets. It will also provide insights on upcoming developments along with a pipeline analysis of vendor operations and the impact of government regulations.
For more insights on this market: Download a Free Sample Report
Technavio has been monitoring the Global Retinal Drugs Market and it is expected to grow by $ 6.28 billion, accelerating at a CAGR of over 6% during the forecast period. The growth trajectory of the market is traced through a detailed analysis of the prevalent market forces, trends, and drivers along with competitive benchmarking. View Free Sample Report
Retinal Drugs Market: Rise in prevalence of retinal diseases to Drive Growth
One of the primary factors that will trigger the growth of the Retinal Drugs Market size the rise in the prevalence of retinal diseases. It has been observed that the prevalence of retinal diseases such as RVO, mCNV, diabetic retinopathy, wet AMD, and DME is high in both developing and developed countries. According to retinal drug market insights, one of the leading causes of visual disability in industrialized countries is AMD.
Similarly, the leading cause of blindness among working-age adults across the globe is diabetic retinopathy. During 2017, almost 185,000 individuals across the globe suffered from age-related macular degeneration (AMD) and it has been predicted that this number will increase to 200,000 by 2022. Similarly, the number of individuals with AMD in Europe will also increase over the next few years and will reach 17 million by 2022.
Retinal Drugs Market: Vendor Analysis
The market is fragmented due to the presence of several players. The growth of the players depends on several factors such as market conditions, government support, and industry development. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions. AbbVie Inc., Aerie Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments.
Technavio offers custom research reports with detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will help clients keep up with new product launches in direct & indirect COVID-19 related markets. It will also provide insights on upcoming developments along with pipeline analysis of vendor operations and the impact of government regulations.
For more insights on this market: Download a Free Sample Report
